Bigfoot Biomedical Inc.
Automated insulin delivery for type 1 diabetes
This article was originally published in Start Up
Each of the four founders of Silicon Valley-based Bigfoot Biomedical Inc. has a spouse or child with type 1 diabetes. That personal connection to the disease drove them to develop an integrated management system to streamline the delivery of the correct amount of insulin and reduce adverse outcomes for the disease.
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."